

Sudan

Eastern Mediterranean Region





I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	34,400,000	87	Plasmodium species: <i>P. falciparum</i> (92%), <i>P. vivax</i> (8%)
Low transmission (0-1 cases per 1000 population)	5,190,000	13	Major anopheles species: <i>An. arabiensis</i> , <i>An. funestus</i> , <i>An. gambiae</i> , <i>An. nili</i> , <i>An. pharoensis</i>
Malaria-free (0 cases)	-	-	Reported confirmed cases (health facility): 575,015 Estimated cases: [855,000–2,222,000]
Total	39,580,000	-	Confirmed cases at community level: - Reported deaths: 984 Estimated deaths: 4,000 [130–8,000]



II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2005	First-line treatment of unconfirmed malaria	AL	2017					
	ITNs/ LLINs distributed to all age groups	Yes	2010	First-line treatment of <i>P. falciparum</i>	AL	2017					
IRS	IRS is recommended	Yes	1956	Treatment failure of <i>P. falciparum</i>	DHA-PPQ	2017					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS; QN	-					
Larval control	Use of larval control recommended	Yes	-	Treatment of <i>P. vivax</i>	AL+PQ(14d)	-					
IPT	IPT used to prevent malaria during pregnancy	No	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2009	Type of RDT used		P.f + P.v specific (Combo)					
	Malaria diagnosis is free of charge in the public sector	No	-								
Treatment	ACT is free of charge for all ages in public sector	Yes	2005	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	2004	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	AL	2010-2015	0	1.4	3.3	28 days	10	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2005	AS+SP	2010-2016	0	4.35	18.1	28 days	14	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	No	-	AL	2011-2011	0	0	0	28 days	1	<i>P. vivax</i>
	Directly observed treatment with primaquine is undertaken	No	-	Insecticide resistance tests (mosquito mortality, %)							
	System for monitoring adverse reactions to antimalarials exists	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
Surveillance	ACD for case investigation (reactive)	No	-	Organophosphates	2010-2015	0.1	0.8	1	63	<i>An. arabiensis</i>	
	ACD of febrile cases at community level (pro-active)	No	-	Organochlorines	2010-2015	0	0.8	1	89	<i>An. arabiensis</i>	
	Mass screening is undertaken	No	-	Carbamates	2010-2016	0	0.9	1	91	<i>An. arabiensis</i>	
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-	Pyrethroids	2010-2015	0	0.7	1	161	<i>An. arabiensis</i>	
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
	Case reporting from private sector is mandatory	No	-								



III. Financing




IV. Coverage



V. Impact



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths (per 100 000)

